U.S. Markets closed

Novocure (NVCR) CFO Wilhelmus Cm Groenhuysen Sold $3.9 million of Shares

CFO of Novocure (30-Year Financial, Insider Trades) Wilhelmus Cm Groenhuysen (insider trades) sold 50,000 shares of NVCR on 09/10/2019 at an average price of $78.19 a share. The total sale was $3.9 million.


NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. NovoCure Ltd has a market cap of $7.7 billion; its shares were traded at around $78.41 with and P/S ratio of 25.16. NovoCure Ltd had annual average EBITDA growth of 27.60% over the past five years.

CEO Recent Trades:

  • CEO Asaf Danziger sold 124,181 shares of NVCR stock on 08/29/2019 at the average price of $91.13. The price of the stock has decreased by 13.96% since.

CFO Recent Trades:

  • CFO Wilhelmus Cm Groenhuysen sold 50,000 shares of NVCR stock on 09/10/2019 at the average price of $78.19. The price of the stock has increased by 0.28% since.

Directors and Officers Recent Trades:

  • General Counsel Todd Christopher Longsworth sold 158,440 shares of NVCR stock on 09/03/2019 at the average price of $87.87. The price of the stock has decreased by 10.77% since.
  • Director Charles G Phillips Iii sold 22,000 shares of NVCR stock on 08/30/2019 at the average price of $91.14. The price of the stock has decreased by 13.97% since.
  • Director W Anthony Vernon sold 100,000 shares of NVCR stock on 08/29/2019 at the average price of $91.03. The price of the stock has decreased by 13.86% since.

For the complete insider trading history of NVCR, click here

.This article first appeared on GuruFocus.